Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.8597
-0.0203 (-2.31%)
At close: May 18, 2026, 4:00 PM EDT
0.8350
-0.0247 (-2.87%)
After-hours: May 18, 2026, 4:53 PM EDT
Valion Bio Employees
Valion Bio had 52 employees as of December 31, 2025. The number of employees increased by 45 or 642.86% compared to the previous year.
Employees
52
Change (1Y)
45
Growth (1Y)
642.86%
Revenue / Employee
n/a
Profits / Employee
-$261,115
Market Cap
2.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 52 | 45 | 642.86% |
| Dec 31, 2024 | 7 | -2 | -22.22% |
| Dec 31, 2023 | 9 | -7 | -43.75% |
| Jun 30, 2023 | 11 | - | - |
| Dec 31, 2022 | 16 | 9 | 128.57% |
| Dec 31, 2021 | 7 | -1 | -12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 19 |
| GeoVax Labs | 19 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Ensysce Biosciences | 10 |
| Indaptus Therapeutics | 5 |
| GRI Bio | 4 |
VBIO News
- 4 days ago - Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform - TheFly
- 4 days ago - Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year - TheFly
- 4 days ago - Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform - PRNewsWire
- 4 days ago - Valion Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS - PRNewsWire
- 7 days ago - Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 - PRNewsWire
- 12 days ago - Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™ - PRNewsWire
- 13 days ago - Valion Bio receives first study protocol under agreement with NIAID - TheFly